AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

Daiichi Sankyo Co. shares dropped the most in three months following a series of discounted block trades in the Japanese pharmaceutical company. The stock sank 7.2% in Tokyo on volume more than 300% ...

Merck announced a significant regulatory milestone with a Breakthrough Therapy designation for its lung cancer drug. This FDA ...

DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the ...

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck’s ifinatamab deruxtecan for patients with pretreated extensivestage SCLC: Tokyo Tuesday, August 19, 2025 ...